Clostridium difficile Colitis

Surgical Clinics of North America

Volumn 89, Issue 2, 2009, Pages 483-500

  Efron, Philip A ^a   Mazuski, John E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; Colitis; Diarrhea; Infection

Indexed keywords

ANTINEOPLASTIC AGENT; BACITRACIN; BACTERIAL TOXIN; CEPHALOSPORIN; CLINDAMYCIN; COLESTYRAMINE; FUSIDIC ACID; GLUTAMATE DEHYDROGENASE; IMMUNOGLOBULIN; METRONIDAZOLE; NITAZOXANIDE; OPIATE DERIVATIVE; PENICILLIN DERIVATIVE; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; RIFALAZIL; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; TIACUMICIN B; TINIDAZOLE; TIZOXANIDE; TOLEVAMER; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIUM DETECTION; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DEHYDRATION; DIARRHEA; DRUG ABSORPTION; DRUG COST; DRUG EFFECT; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FECES CULTURE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; LATEX AGGLUTINATION TEST; LETHARGY; NAUSEA; PATHOGENESIS; POLYMERASE CHAIN REACTION; POLYNEUROPATHY; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RISK FACTOR; SACCHAROMYCES BOULARDII; SYMPTOM; TACHYCARDIA; VOMITING;

AGE FACTORS; ANTIBIOTIC PROPHYLAXIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; RECURRENCE; RISK FACTORS;

EID: 61549106962     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2008.09.014     Document Type: Review

References (133)

1. Bartlett J.G., and Gerding D.N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 46 (2008) S12-S18
2. McDonald L.C., Kilgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353 23 (2005) 2433-2441
3. Sunenshine R.H., and McDonald L.C. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 73 (2006) 187-197
4. Bartlett J.G., and Perl T.M. The new Clostridium difficile: what does it mean?. N Engl J Med 353 (2005) 2503-2505
5. Hubert B., Loo V.G., Bourgault A.M., et al. A portrait of the geographic dissemination of the Clostridium difficile colitis North American pulsed-field type 1 strain and the epidemiology of C difficile-associated disease in Quebec. Clin Infect Dis 44 (2007) 238-244
6. Dallal R.M., Harbrecht B.G., Boujoukas A.J., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 235 (2002) 363-372
7. Kyne L., Hamel M.B., Polavaram R., et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 24 (2002) 346-353
8. Viscidi R., Willey S., and Bartlett J.G. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 81 (1981) 5-9
9. McFarland L.V., Mulligan M.E., Kwok R.Y.Y., et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320 (1989) 204-210
10. Bender B.S., Bennett R., Laughon B.E., et al. Is Clostridium difficile endemic in chronic care facilities?. Lancet 2 (1986) 11-13
11. Johnson S., Clabots C.R., Linn F.V., et al. Clostridium difficile colonization and disease. Lancet 336 (1990) 97-100
12. Mazuski J.E., and Longo W.E. Clostridium difficile colitis. Problems in General Surgery 19 1 (2002) 121-132
13. Fordtran J.S. Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial. Proc (Bayl Univ Med Cent) 19 (2006) 3-12
14. Bartlett J.G. Clostridium difficile: clinical considerations. Rev Infect Dis 12 Suppl 2 (1990) S243-S251
15. Reinke C.M., and Messick C.R. Update on Clostridium difficile-induced colitis, part 1. Am J Hosp Pharm 51 (1994) 1771-1781
16. Wilson K.H. The microecology of Clostridium difficile. Clin Infect Dis 16 Suppl 4 (1993) S214-S218
17. Bignardi G.E. Risk factors for Clostridium difficile infection. J Hosp Infect 40 (1998) 1-15
18. Kelly C.P., Pothoulakis C., and LaMont J.T. Clostridium difficile colitis. N Engl J Med 330 (1994) 257-262
19. Kelly C.P., and LaMont T.J. Clostridium difficile infection. Annu Rev Med 49 (1998) 375-390
20. Riegler M., Sedivy R., Pothoulakis C., et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 95 (1995) 2004-2011
21. Hurley B.W., and Nguyen C.C. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 162 (2002) 2177-2184
22. Adams S.D., and Mercer D.W. Fulminant Clostridium difficile colitis. Curr Opin Crit Care 13 (2007) 450-455
23. MacCannell D.R., Louie T.J., Gregson D.B., et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol 44 (2006) 2147-2152
24. Weiss K., Bergeron L., Bernatchez H., et al. Clostridium difficile-associated diarrhoea rates and global antibiotic consumption in five Quebec institutions from 2001 to 2004. Int J Antimicrob Agents 30 (2007) 309-314
25. Gerding D.N., Muto C.A., and Owens R.C. Treatment of Clostridium difficile infection. Clin Infect Dis 46 (2008) S32-S42
26. Pepin J. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic?. Clin Infect Dis 46 (2008) 1493-1498
27. Rupnik M., Avesani V., Janc M., et al. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 36 (1998) 2240-2247
28. Geric B., Rupnik M., Gerding D.N., et al. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 53 (2004) 887-894
29. Warny M., Pepin J., Fang A., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 (2005) 1079-1084
30. McDonald L.C., Owings M., and Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12 (2006) 409-415
31. Redelings M.D., Sorvillo F., and Mascola L. Increase in Clostridium difficile-related mortality, United States, 1999-2004. Emerg Infect Dis 13 (2007) 1417-1419
32. Ricciardi R., Rothenberger D.A., Madoff R.D., et al. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 142 (2007) 624-631
33. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 23 (2005) 2442-2449
34. Musher D.M., Aslam S., Logan N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40 (2005) 1586-1590
35. Bourgault A.M., Lamothe F., Loo V.G., et al. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Quebec. Antimicrob Agents Chemother 50 (2006) 3473-3475
36. Privitera G., Scarpellini P., Ortisi G., et al. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 35 (1991) 208-210
37. Bartlett J.G. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 346 (2002) 334-339
38. Gaynes R., Rimland D., Killum E., et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxicin use. Clin Infect Dis 38 (2004) 640-645
39. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinilones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41 (2005) 1254-1260
40. Bartlett J.G. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 18 Suppl 4 (1994) S265-S272
41. Simor A.E., Bradley S.F., Strausbaugh L.J., et al. Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 23 (2002) 696-703
42. Chang V.T., and Nelson K. The role of physical proximity in nosocomial diarrhea. Clin Infect Dis 31 (2000) 717-722
43. Aronsson B., Molly R., and Nord C.E. Diagnosis and epidemiology of Clostridium difficile-associated diarrhea in Sweden. The Swedish C difficile Study Group. J Antimicrob Chemother 14 Suppl D (1984) 85-95
44. Yolken R.H., Bishop C., Townsend T.R., et al. Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med 306 (1982) 1010-1012
45. Mogg G.A., Keighley M.R., Burdon D.W., et al. Antibiotic-associated colitis: a review of 66 cases. Br J Surg 66 (1979) 738-742
46. Bartlett J.G., Taylor N.S., Chang T., et al. Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr 33 11 Suppl (1980) 2521-2526
47. Tedesco F.J., Barton R.W., and Alpers D.H. Clindamycin-associated colitis: a prospective study. Ann Intern Med 81 (1974) 429-433
48. Longo W.E., Mazuski J.E., Virgo K.S., et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 47 10 (2004) 1620-1626
49. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 92 (1997) 739-750
50. Schue V., Green G.A., and Monteil H. Comparison of the ToxA test with cytotoxicity assay and culture for the detection of Clostridium difficile-associated diarrhoeal disease. J Med Microbiol 41 (1994) 316-318
51. Mylonakis E., Ryan E.T., and Calderwood S.B. Clostridium difficile-associated diarrhea. Arch Intern Med 161 (2001) 525-533
52. Wilkins T.D., and Lyerly D.M. Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol 41 (2003) 531-534
53. Chang T.W., Bartlett J.G., Gorbach S.L., et al. Clindamycin-induced enterocolitis in hamsters a as a model of pseudomembranous colitis in patients. Infect Immun 20 (1978) 526-529
54. Borek A.P., Aird D.Z., and Carroll K.C. Frequency of sample submission for optimal utilization of the cell culture cytotoxicity assay for detection of Clostridium difficile toxin. J Clin Microbiol 43 (2005) 2994-2995
55. Whittier S., Shapiro D.S., Kelly W.F., et al. Evaluation of four commercially available enzyme immunoassays for laboratory diagnosis of Clostridium difficile-associated diseases. J Clin Microbiol 31 (1993) 2861-2865
56. Merz C.S., Kramer C., Forman M., et al. Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens. J Clin Microbiol 32 (1994) 1142-1147
57. Delmee M., Van Broeck J., Simon A., et al. Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture. J Med Microbiol 54 (2005) 187-191
58. George W.L., Sutter V.L., Citron D., et al. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 9 (1979) 214-219
59. Shanholtzer C.J., Willard K.E., Holter J.J., et al. Comparison of the Vidas Clostridium difficile toxin A immunoassay with C difficile culture and cytotoxin and latex tests. J Clin Microbiol 30 (1992) 1837-1840
60. Ticehurst J.R., Aird D.Z., Dam L.M., et al. Effective detection of toxigenic Clostridium difficile by a two step algorithm including test for antigen and cytotoxin. J Clin Microbiol 44 (2006) 1145-1149
61. Manabe Y.C., Vinetz J.M., Moore R.D., et al. Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med 123 (1995) 835-840
62. Kato N., Ou C.Y., Kato H., et al. Detection of toxigenic Clostridium difficile in stool specimens by the polymerase chain reaction. J Infect Dis 167 (1993) 455-458
63. National Clostridium difficile Standards Group: report to the Department of Health. J Hosp Infect 56 Suppl 1 (2004) 1-38
64. Riley T.V., Cooper M., Bell B., et al. Community-acquired Clostridium difficile-associated diarrhea. Clin Infect Dis 20 Suppl 2 (1995) S263-S265
65. Tedesco F.J., Corless J.K., and Brownstein R.E. Rectal sparing in antibiotic-associated pseudomembranous colitis: a prospective study. Gastroenterology 83 (1982) 1259-1260
66. Tedesco F.J. Antibiotic associated pseudomembranous colitis with negative proctosigmoidoscopy examination. Gastroenterology 77 (1979) 295-297
67. Fisherman E.K., Kavuru M., Jones B., et al. Pseudomembranous colitis: CT evaluation of 26 cases. Radiology 180 (1991) 57-60
68. Kawamoto S., Horton K.W., and Fishman E.K. Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. Radiographics 19 (1999) 887-897
69. Hayetian F.D., Read T.E., Brozovich M., et al. Ileal perforation secondary to Clostridium difficile enteritis: report of 2 cases. Arch Surg 141 1 (2006) 97-99
70. Fekety R., and Shah A.B. Diagnosis and treatment of Clostridium difficile colitis. JAMA 269 (1993) 71-75
71. Bartlett J.G. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 46 (2008) 1489-1492
72. Teasley D.G., Gerding D.N., Olson M.M., et al. Prospective randomized trial of metronidazole vs. vancomycin fro Clostridium difficile-associated diarrhea and colitis. Lancet 2 (1983) 1043-1046
73. Fekety R., Silva J., Buggy B., et al. Treatment of antibiotic-associated colitis with vancomycin. J Antimicrob Chemother 12 Suppl D (1984) 97-102
74. Bartlett J.G., Tedesco F.J., Shull S., et al. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 78 (1980) 431-434
75. Gerding D.N., Johnson S., Peterson L.R., et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 16 (1995) 459-477
76. Fekety R., Silva J., Kauffman C., et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 86 (1989) 15-19
77. Poutanen S.M., and Simor A.E. Clostridium difficile-associated diarrhea in adults. CMAJ 171 (2004) 51-58
78. Bolton R.P., and Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27 (1986) 1169-1172
79. Johnson S., Hormann S.R., Bettin K.M., et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo controlled trial. Ann Intern Med 117 (1992) 297-302
80. Zar F.A., Bakkanagari S.R., Moorthi M.K.L.S.T., et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45 (2007) 302-307
81. Lagrotteria D., Holmes S., Smieja M., et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 3 (2006) 547-552
82. Pepin J., Valiquette L., Gagnon S., et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 102 (2007) 2781-2788
83. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145 (2006) 758-764
84. Pepin J., Routhier S., Gagnon S., et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 42 (2006) 758-764
85. McFarland L.V., Elmer G.W., and Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97 (2002) 1769-1775
86. De Lalla F., Nicolin R., Rinaldi E., et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 36 (1992) 2192-2196
87. Wenisch C., Parschalk B., Hasenundl M., et al. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 22 (1996) 813-818
88. Louie T., Gerson M., Grimard D., et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea (CDAD). [abstract K-4259]. Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC) (2007), ASM Press, Herndon (VA)
89. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 3 (2007) CD004610
90. Aslam S., and Musher D.M. An update on diagnosis, treatment and prevention of Clostridium difficile-associated disease. Gastroenterol Clin North Am 35 (2006) 315-335
91. Malnick S.D., and Zimhony O. Treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 36 (2002) 1767-1775
92. Musher D.M., Logan N., Hamill R.J., et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 43 (2006) 421-427
93. Musher D.M., Logan N., Mehendiratta V., et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 59 (2007) 705-710
94. Louie T.J., Peppe J., Watt C.K., et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 43 (2006) 411-420
95. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271 (1994) 1913-1918
96. Surawicz C.M., McFarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31 (2000) 1012-1017
97. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101 (2006) 812-822
98. Dendukuri N., Costa V., McGregor M., et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 173 (2005) 167-170
99. Cassone M., Serra P., Mondello F., et al. Outbreak of Saccharomyces cerevisiae subtype boulardii infection fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 41 (2003) 5340-5343
100. Enache-Angoulvant A., and Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 41 (2005) 1559-1568
101. Lherm T., Monet C., Nougiere B., et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 28 (2002) 797-801
102. Salminen M.K., Rautelin H., Tynkkynen S., et al. Lactobacills bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 38 (2004) 62-69
103. Pelaez T., Alcala L., Alonso R., et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 48 (2004) 2280-2282
104. Ackermann G., Loffler B., Adler D., et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 48 (2004) 2280-2282
105. Anton P.M., O'Brien M., Kokkotou E., et al. Rifalazil treats and prevents relapse of Clostridium difficile-associated diarrhea in hamsters. Antimicrob Agents Chemother 48 (2004) 3975-3979
106. Citron D.M., Tyrell K.L., Warren Y.A., et al. In vitro activities of tinidazole and metronidazole against Clostridium difficile, Prevotella bivia, and Bacteroides fragilis. Anaerobe 113 (2005) 15-17
107. Adachi J.A., and DuPont H.L. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 42 (2006) 541-547
108. Taylor D.N., Bourgeois A.L., Ericsson C.D., et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 74 (2006) 1060-1066
109. Pepin J., Alary M.E., Valiquette L., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40 (2005) 1591-1597
110. Barbut F., Richard A., Hamadi K., et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 38 (2000) 2386-2388
111. McFarland L.V. Alternative treatments for Clostridium difficile disease: what really works?. J Med Microbiol 54 (2005) 101-111
112. McFarland L.V., Surawicz C.M., Rubin M., et al. Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 20 (1999) 43-50
113. Aas J., Gessert C.E., and Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via nasogastric tube. Clin Infect Dis 36 (2003) 580-585
114. Sanchez J.L., Gerding D.N., Olson M.M., et al. Metronidazole susceptibility in Clostridium difficile isolates recovered from cases of C difficile-associated disease treatment failures and successes. Anaerobe 5 (1999) 201-204
115. Kyne L., Warny M., Qamar A., et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357 (2001) 189-193
116. Nair S., Yadav D., Corpuz M., et al. Clostridium difficile colitis: factors influencing treatment failure and relapse - prospective evaluation. Am J Gastroenterol 93 (1998) 1873-1876
117. Buggy B.P., Fekety R., and Silva Jr. J. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 9 (1987) 155-159
118. Taylor N.S., and Bartlett J.G. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 141 (1980) 92-97
119. Johnson S., Schriever C., Galang M., et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44 (2007) 846-848
120. Olson M.M., Shanholtzer C.J., Lee J.T., et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 15 (1994) 371-381
121. Pasic M., Jost R., Carrel T., et al. Intracolonic vancomycin for pseudomembranous colitis. N Engl J Med 329 (1993) 583
122. Lamontagne F., Labbe A.C., Haeck O., et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 245 (2007) 267-272
123. Morris J.B., Zollinger R.M., and Stellato T.A. Role of surgery in antibiotic-induced pseudomembranous enterocolitis. Am J Surg 160 (1990) 535-539
124. Drapkin M.S., Worthington M.G., Chang T.W., et al. Clostridium difficile colitis mimicking acute peritonitis. Arch Surg 120 (1985) 1321-1322
125. Lipsett P.A., Samantaray D.L., Tam M.L., et al. Pseudomembranous colitis: a surgical disease?. Surgery 116 (1994) 491-496
126. Synott K., Mealy K., Merry C., et al. Timing of surgery for fulminating pseudomembranous colitis. Br J Surg 85 (1998) 229-231
127. Medich D.S., Lee K.K., Simmons R.L., et al. Laparotomy for fulminant pseudomembranous colitis. Arch Surg 127 (1992) 847-853
128. Bradbury A.W., and Barrett S. Surgical aspects of Clostridium difficile colitis. Br J Surg 84 (1997) 150-159
129. Grundfest-Broniatowski S., Quader M., Alexander F., et al. Clostridium difficile colitis in the critically ill. Dis Colon Rectum 39 (1996) 619-623
130. Samore M.H., Venkataraman L., DeGirolami P.C., et al. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 100 (1996) 32-40
131. Garner J.S. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 17 (1996) 53-80 [Erratum, Infect Control Hosp Epidemiol 1996;17:214]
132. Sehulster L., and Chinn R.Y. Guidelines for environmental infection control in healthcare facilities: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee [HICPAC]. MMWR Recomm Rep 55 RR-10 (2003) 1-42
133. Boyce J.M., and Pittet D. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 23 Suppl (2002) S3-S40